Balchem's Third Quarter 2026 Earnings Call - BALCHEM CORP

Financial Performance:

• Consolidated net sales reached a record $291 million, an 8.6% year-over-year increase.
• GAAP net income hit $47 million (up 16%), with diluted EPS of $1.46 (up 17.7%).
• Adjusted EBITDA recorded a record $80 million, up 12.4%, representing a 27.6% margin.
• Adjusted net earnings were $50 million (up 14.5%), or $1.57 per diluted share (up 16.3%).
• Gross margin expanded 70 basis points to 36.4%, driven by favorable product mix and manufacturing efficiencies, partially offset by higher input costs.
• Operating expenses rose to $43 million due to higher compensation, partially offset by discrete items.
• Net interest expense decreased to $2 million due to lower borrowings and interest rates.
• Cash flow from operations was $70 million; free cash flow was $58 million.
• Balance sheet strength included $66 million in cash, net borrowings reduction of $28 million, and a net leverage ratio of 0.2x.
• The company repurchased $28 million of common stock during the quarter.
• Effective tax rate was 22.2%, with guidance to remain in the 22.5%–23% range for the full year.

Guidance and Future Outlook:

• Expects Q4 2026 sales to be sequentially lower than Q3 due to historic seasonality, but remains confident in delivering year-over-year growth.
• Management noted 29 consecutive quarters of year-over-year adjusted EBITDA growth.
• Long-term outlook remains positive, supported by "better-for-you" trends and market penetration of specialty nutrients.
• Company is well-positioned to fund innovation and acquisitions via an expanded $650 million credit facility and strong cash generation.

Business Segments and Product Lines:

• Human Nutrition and Health: Sales of $188 million (+8.1%); record operating earnings of $46 million (+11.8%). Growth driven by nutrients and food ingredients/solutions.
• Animal Nutrition and Health: Sales of $63 million (+11.7%); operating earnings of $6.8 million (+82.8%). Growth fueled by ruminant/monogastric adoption of protected nutrients, pricing actions, and EU anti-dumping duty impacts.
• Specialty Products: Sales of $37 million (+4.5%); operating earnings of $12 million (+6.6%). Driven by steady demand for performance gases.
• New Product Launches: Rolled out next-generation encapsulated methionine on October 1st; previously launched encapsulated glycine.
• Scientific Updates: Published two key studies: (1) MD Anderson/Alzheimer's Association study on Choline's potential role in adult cognitive health; (2) DANCODE trial in Circulation supporting Vitamin K2's cardiovascular benefits regarding coronary artery calcification.

Market and Competitive Landscape:

• Healthy demand across human nutrition, animal nutrition, and specialty gases.
• Animal nutrition segment benefiting from anti-dumping duties in Europe and US, though circumvention efforts persist.
• US anti-dumping filing recently initiated to combat dumping in the monogastric sector.
• Fracking industry demand for choline chloride remains low ($8M run rate) despite high oil prices, as customers have reformulated and increased fluid reuse.
• Company plans to announce a new international sports partnership (potentially football/soccer) within the next month.

Risks and Challenges:

• Inflationary pressure on raw materials and logistics; company aims to pass costs to customers to remain roughly break-even on margin impact.
• Potential for trade practice violations (circumvention of anti-dumping duties) in both EU and US markets.
• Geopolitical instability necessitates holding higher safety stock, contributing to inventory increases.
• High oil prices viewed as a net negative due to increased input and utility costs.

Management Commentary and Tone:

• Tone was highly confident and positive, citing "excellent quarter" and "record results."
• Emphasized the resilience of the business model and the strength of the science-backed portfolio.
• CEO Ted Harris and CFO Martin Bengtsson highlighted strategic execution on growth initiatives and the "break-even" result on inflation pass-through as a key success.
• Management reiterated commitment to investing in clinical science to support marketing and brand differentiation.

Analyst Questions and Answers:

• Inflation & Margins: Confirmed favorable mix in Human Nutrition (higher-margin nutrients growing faster than food ingredients) and Animal Nutrition (higher-margin ruminant vs. monogastric). Inflation pass-through is nearly complete year-to-date.
• Inventory Levels: Explained the rise to $177 million due to four factors: inflation (higher unit costs), growth-driven needs, strategic safety stock for geopolitical risks, and preparation for upcoming product launches.
• Future Clinical Studies: Confirmed ongoing research into exercise recovery, sleep (magnesium), beauty (MSM for hair/nail/skin), liver health, and energy/focus (choline).
• Partnerships: Confirmed active exploration of partnerships in the aesthetic/beauty sector and plans for a new global sports sponsorship announcement soon.
• Tax Rate: Guidance remains 22.5%–23% for the full year.

Other Key Points:

• Next earnings call scheduled for February 2027.
• Upcoming conference attendance: Baird Global Industrial Conference (Nov 11, 2026) and CJS Securities Virtual Conference (Jan 7, 2027).
• The transcript contains a recurring transcription error referring to the company as "Balcombe" or "Valchem" in the spoken audio, though context clearly identifies the company as Balchem Corporation.